NeuroOne's OneRF Ablation Shows Promise in Drug-Resistant Epilepsy

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced promising real-world results from a large cohort of epilepsy patients treated with its OneRF® Ablation System at the Mayo Clinic in Jacksonville, Florida. The study, led by neurologist Dr. Brin Freund and the late neurosurgeon Dr. Sanjeet Grewal, involved 25 patients with drug-resistant focal epilepsy. After diagnostic stereo-EEG (SEEG) monitoring using NeuroOne electrodes, physicians performed radiofrequency (RF) ablations on seizure foci. The procedure was well tolerated, with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, and some achieved sustained seizure freedom. Most patients also reported improved quality of life and satisfaction with the procedure. These findings, highlighted in a NEWMEDIAWIRE release, validate the OneRF system's ability to deliver controlled, temperature-based treatment while allowing real-time assessment and additional targeted ablations during the same monitoring period.

Dr. Freund noted that SEEG-guided radiofrequency thermocoagulation is a minimally invasive bedside procedure that uses the same implanted diagnostic electrodes to localize and treat seizures. He emphasized the ability to precisely target seizure-generating tissue while preserving normal brain function. The technology provides real-time feedback on ablation effectiveness, enabling physicians to perform additional ablations as needed. This approach has become part of the standard of care at Mayo Clinic Florida, reflecting a shift in the treatment paradigm for drug-resistant focal epilepsy.

Dave Rosa, CEO of NeuroOne, expressed gratitude to the Mayo Clinic team for evaluating the technology and sharing their experience. He stated that these results validate the compelling clinical and economic value of combining SEEG diagnosis and RF ablation through the same implanted electrodes. NeuroOne's proprietary temperature monitoring technology provides real-time treatment feedback, enhancing physician confidence during ablation. As the only FDA-cleared platform integrating SEEG diagnosis and RF ablation using the same sEEG device, NeuroOne is uniquely positioned to support this diagnosis-to-therapy paradigm. The company markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. For more information, visit nmtc1.com.